9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma

Condition Advanced Malignant Pleural Mesothelioma Estimated Enrollment: 26 Age Group: 18 Years to 75 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: INCANOGAR2012-JA3 Study First Received: April 18, 2012 Last Updated: March 1, 2017 Estimated Primary Completion Date: December 2017 Primary Outcome Measures: Evaluate adverse effects to 250 mg/m2 infusion gemcitabine|Progression Free Survival|overall survival Sponsors and Collaborators: Instituto Nacional de Cancerologia de Mexico|National Council of Science and Technology, Mexico Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01869023...

Continue reading

Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107

Condition Malignant Mesothelioma Estimated Enrollment: 47 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case-Only|Time Perspective: Prospective Study ID Numbers: CALGB-150509|U10CA031946|CDR0000491313 Study First Received: May 9, 2009 Last Updated: July 1, 2016 Estimated Primary Completion Date: March 2006 Primary Outcome Measures: Level of biomarkers, including thrombospondin I, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin (high vs low)|Effect of biomarker expression level on overall survival Sponsors and Collaborators: Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00898547...

Continue reading

Malignant Mesothelioma – Can we Improve Quality of Life

Condition Mesothelioma, Malignant Estimated Enrollment: 319 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Supportive Care Study ID Numbers: PHT/2013/46 Study First Received: January 4, 2017 Last Updated: March 1, 2017 Estimated Primary Completion Date: March 2017 Primary Outcome Measures: EORTC C-30 Quality of Life|Health Related Quality of Life (HRQoL) in Patients|Patient Mood|Primary Caregiver Health Related Quality of Life (HRQoL)|Primary Caregiver Mood|Overall Survival between the two study groups|Healthcare Utilisation between the two study groups|Primary caregiver satisfaction with end of life care Sponsors and Collaborators: Portsmouth Hospitals NHS Trust|British Lung Foundation|University of Oxford Result Received: No Study Results Posted Website...

Continue reading

Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients

Condition Malignant Mesothelioma Estimated Enrollment: 100 Age Group: Child, Adult, Senior Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case-Only|Time Perspective: Prospective Study ID Numbers: ONC/OSS-02/2011 Study First Received: May 27, 2013 Last Updated: July 20, 2016 Estimated Primary Completion Date: December 2017 Primary Outcome Measures: dissect the molecular mechanisms underlying the development of malignant mesothelioma|study of the effect of TAMs|investigation of molecular mechanisms linking macrophages|molecular characterization (proteome) of TAMs and tumor cells|compare in specimens from mesothelioma patients and the candidate molecular markers|Investigate the association of selected markers with Overall Survival Sponsors and Collaborators: Armando Santoro, MD|Istituto Clinico Humanitas Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02300883...

Continue reading

Response Evaluation in Malignant Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 150 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Retrospective Study ID Numbers: ONC/OSS-02/2009 Study First Received: August 6, 2009 Last Updated: August 5, 2015 Estimated Primary Completion Date: August 2015 Primary Outcome Measures: To validate a semi-automated iterative threshold-based region growing algorithm in a previously published series of patients.|To extend the analysis to another series of consecutive patients with MALIGNANT PLEURAL MESOTHELIOMA treated with first-line pemetrexed-based chemotherapy, and to perform a combined analysis of the two groups.|To validate the new liver-based threshold semi-automated algorithm on the GE ADW4.6 workstation with the algorithm...

Continue reading

Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma

Condition Mesothelioma Estimated Enrollment: 107 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Supportive Care Study ID Numbers: 11-066 Study First Received: May 17, 2011 Last Updated: April 17, 2017 Estimated Primary Completion Date: November 2018 Primary Outcome Measures: To describe the psychological needs of patients with mesothelioma.|the aim is to explore the acceptability and promise of an Internet-based discussion group for patients with mesothelioma. Sponsors and Collaborators: Memorial Sloan Kettering Cancer Center Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01356251...

Continue reading

Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 12 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 1716-12 Study First Received: October 22, 2012 Last Updated: September 8, 2016 Estimated Primary Completion Date: March 2017 Primary Outcome Measures: Safety and tolerability of HSV1716 given by single and repeat intrapleural administration in patients with inoperable malignant pleural mesothelioma.|Obtain evidence of HSV1716 replication and lysis of malignant pleural mesothelioma cells through analysis of pleural fluid and serum samples for evidence of cell death and/or HSV1716 replication and/or changes in appropriate biomarkers. Sponsors and Collaborators: Virttu Biologics Limited Result...

Continue reading

Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy

Condition Pleural Mesothelioma|Peritoneal Mesothelioma Estimated Enrollment: 20 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 100146|10-C-0146 Study First Received: July 9, 2010 Last Updated: August 31, 2016 Estimated Primary Completion Date: April 2012 Primary Outcome Measures: Clinical Response Rate (PR+CR)|Safety of IMC-A12 in Patients With Mesothelioma Sponsors and Collaborators: National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Result Received: March 20, 2013 Website Link: https://ClinicalTrials.gov/show/NCT01160458...

Continue reading